NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.

We and others previously identified NKX2-1, also known as TITF1 and TTF-1, as a lineage-survival oncogene in lung adenocarcinomas. Here we show that NKX2-1 induces the expression of the receptor tyrosine kinase-like orphan receptor 1 (ROR1), which in turn sustains a favorable balance between prosurvival PI3K-AKT and pro-apoptotic p38 signaling, in part through ROR1 kinase-dependent c-Src activation, as well as kinase activity-independent sustainment of the EGFR-ERBB3 association, ERBB3 phosphorylation, and consequential PI3K activation. Notably, ROR1 knockdown effectively inhibited lung adenocarcinoma cell lines, irrespective of their EGFR status, including those with resistance to the EGFR tyrosine kinase inhibitor gefitinib. Our findings thus identify ROR1 as an "Achilles' heel" in lung adenocarcinoma, warranting future development of therapeutic strategies for this devastating cancer.

[1]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[2]  W. Sellers,et al.  Lineage dependency and lineage-survival oncogenes in human cancer , 2006, Nature Reviews Cancer.

[3]  Sreenath V. Sharma,et al.  ErbBs in lung cancer. , 2009, Experimental cell research.

[4]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[5]  V. Boggaram.  Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. , 2009, Clinical science.

[6]  Y. Yatabe,et al.  ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. , 2005, Cancer research.

[7]  Frank McCormick,et al.  Akt activation by growth factors is a multiple-step process: the role of the PH domain , 1998, Oncogene.

[8]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[9]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[10]  Y. Yatabe,et al.  Establishment of human peripheral lung epithelial cell lines (HPL1) retaining differentiated characteristics and responsiveness to epidermal growth factor, hepatocyte growth factor, and transforming growth factor beta1. , 1997, Cancer research.

[11]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[12]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[13]  W. Forrester.  The Ror receptor tyrosine kinase family , 2002, Cellular and Molecular Life Sciences CMLS.

[14]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[15]  Jeffrey A Whitsett,et al.  Transcriptional control of lung morphogenesis. , 2007, Physiological reviews.

[16]  Y. Yatabe,et al.  Molecular and Cellular Pathobiology Mir-375 Is Activated by Ash1 and Inhibits Yap1 in a Lineage-dependent Manner in Lung Cancer , 2022 .

[17]  T. Hunter,et al.  Requirement for c-Src Catalytic Activity and the SH3 Domain in Platelet-derived Growth Factor BB and Epidermal Growth Factor Mitogenic Signaling* , 1996, The Journal of Biological Chemistry.

[18]  G. Carpenter,et al.  ErbB receptors: new insights on mechanisms and biology. , 2006, Trends in cell biology.

[19]  C. Larsson,et al.  Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy , 2008, International journal of cancer.

[20]  Shuta Tomida,et al.  Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. , 2008, Cancer research.

[21]  D. Haber,et al.  A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. , 2006, Cancer cell.

[22]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[23]  Hua Guo,et al.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.

[24]  Takayuki Kosaka,et al.  Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Y. Qiu,et al.  Regulation of Akt/PKB Activation by Tyrosine Phosphorylation* , 2001, The Journal of Biological Chemistry.

[26]  L. Rassenti,et al.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a , 2008, Proceedings of the National Academy of Sciences.

[27]  Y. Yatabe,et al.  Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.

[28]  Y. Yatabe,et al.  TTF-1 Expression in Pulmonary Adenocarcinomas , 2002, The American journal of surgical pathology.

[29]  C. Mermel,et al.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Y. Yatabe,et al.  Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. , 2007, Cancer research.

[31]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .

[32]  D. Haber,et al.  Modeling oncogene addiction using RNA interference , 2008, Proceedings of the National Academy of Sciences.

[33]  G. Martin.  The hunting of the Src , 2001, Nature Reviews Molecular Cell Biology.

[34]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[35]  Yiling Lu,et al.  Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades* , 2003, Journal of Biological Chemistry.

[36]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[37]  Y. Qiu,et al.  Interaction between Src and a C-terminal Proline-rich Motif of Akt Is Required for Akt Activation* , 2003, The Journal of Biological Chemistry.

[38]  J. Brugge,et al.  Src kinase activation by direct interaction with the integrin β cytoplasmic domain , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C H Fox,et al.  The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. , 1996, Genes & development.

[40]  A. Brunet,et al.  The FoxO code , 2008, Oncogene.

[41]  Y. Yatabe,et al.  EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.

[42]  I Petersen,et al.  Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer , 2008, Oncogene.

[43]  P. Sternberg,et al.  Ror receptor tyrosine kinases: orphans no more. , 2008, Trends in cell biology.

[44]  Jude Kendall,et al.  Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.

[45]  Y. Minami,et al.  Ror‐family receptor tyrosine kinases in noncanonical Wnt signaling: Their implications in developmental morphogenesis and human diseases , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

[46]  Adrian Wiestner,et al.  Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia , 2008, Clinical Cancer Research.

[47]  K. Okudela,et al.  Small Cell Lung Cancer: Significance of RB Alterations and TTF-1 Expression in its Carcinogenesis, Phenotype, and Biology , 2009, Endocrine pathology.